Hansa Biopharma initiated with an Outperform at Wedbush

Wedbush initiated coverage of Hansa Biopharma (HNSBF) with an Outperform rating and SEK 69 price target The firm views Hansa Biopharma as a compelling, de-risked commercial story spanning organ transplants, autoimmune disease, and gene therapy. Lead asset imlifidase is already approved in Europe for desensitization of highly sensitized kidney transplant patients and is poised to become the first FDA-approved therapy in this setting, supported by positive Phase 3 ConfIdeS data and a BLA submission in December 2025. Wedbusg believes Hansa is an attractive acquisition candidate for mid-to-large size companies with nephrology franchises given its unique positioning in kidney transplantation, low integration complexity, and the potential to divest its EU operations for increased focus and synergy.